Homologous recombination-based gene therapy for the primary immunodeficiencies

Annals of the New York Academy of Sciences

Volumn 1246, Issue 1, 2011, Pages 131-140

  Porteus, Matthew ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Gene targeting; Homologous recombination; Severe combined immunodeficiency; TAL effector nuclease; Zinc finger nuclease

Indexed keywords

NUCLEASE;

BONE MARROW TRANSPLANTATION; GENE THERAPY; HOMOLOGOUS RECOMBINATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; LEUKEMIA; NONHUMAN; REVIEW; TREATMENT INDICATION; VIRAL GENE THERAPY;

EID: 84855303364     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06314.x     Document Type: Review

References (56)

1. Buckley, R.H. 2000. Advances in the understanding and treatment of human severe combined immunodeficiency. Immunol. Res. 22: 237-251.
2. Gennery, A.R. et al. 2010. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J. Allergy Clin. Immunol. 126: 602-610 e601-e611.
3. Stephan, V. et al. 1996. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N. Engl. J. Med. 335: 1563-1567.
4. Bousso, P. et al. 2000. Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. Proc. Natl. Acad. Sci. USA 97: 274-278.
5. Fischer, A. et al. 2002. Gene therapy for human severe combined immunodeficiencies. Isr. Med. Assoc. J. 4: 51-54.
6. Fischer, A., S. Hacein-Bey-Abina & M. Cavazzana-Calvo. 2010. 20 years of gene therapy for SCID. Nat. Immunol. 11: 457-460.
7. Cavazzana-Calvo, M. et al. 2005. Gene therapy for severe combined immunodeficiency. Annu Rev. Med. 56: 585-602.
8. Aiuti, A. et al. 2009. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360: 447-458.
9. Boztug, K. et al. 2010. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 363: 1918-1927.
10. Ott, M.G. et al. 2006. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12: 401-409.
11. Stein, S. et al. 2010. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16: 198-204.
12. Sedivy, J.M. & P.A. Sharp. 1989. Positive genetic selection for gene disruption in mammalian cells by homologous recombination. Proc. Natl. Acad. Sci. USA 86: 227-231.
13. Porteus, M.H. & D. Baltimore. 2003. Chimeric nucleases stimulate gene targeting in human cells. Science 300: 763.
14. Doetschman, T., N. Maeda & O. Smithies. 1988. Targeted mutation of the Hprt gene in mouse embryonic stem cells. Proc. Natl. Acad. Sci. USA 85: 8583-8587.
15. Thomas, K.R. & M.R. Capecchi. 1987. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51: 503-512.
16. Smithies, O. et al. 1985. Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature 317: 230-234.
17. Sedivy, J.M. & A. Dutriaux. 1999. Gene targeting and somatic cell genetics-a rebirth or a coming of age? Trends Genet. 15: 88-90.
18. Jasin, M. 1996. Genetic manipulation of genomes with rare-cutting endonucleases. Trends Genet. 12: 224-228.
19. Rouet, P., F. Smih & M. Jasin. 1994. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc. Natl. Acad. Sci. USA 91: 6064-6068.
20. Sargent, R.G., M.A. Brenneman & J.H. Wilson. 1997. Repair of site-specific double-strand breaks in a mammalian chromosome by homologous and illegitimate recombination. Mol. Cell. Biol. 17: 267-277.
21. Choulika, A. et al. 1995. Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccaromyces cerevisiae. Mol. Cell. Biol. 15: 1968-1973.
22. Stoddard, B.L. 2011. Homing endonucleases: from microbial genetic invaders to reagents for targeted DNA modification. Structure 19: 7-15.
23. Paques, F. & P. Duchateau. 2007. Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy. Curr. Gene. Ther. 7: 49-66.
24. Wyman, C., D. Ristic & R. Kanaar. 2004. Homologous recombination-mediated double-strand break repair. DNA Repair 3: 827-833.
25. Weinstock, D.M. et al. 2006. Modeling oncogenic translocations: distinct roles for double-strand break repair pathways in translocation formation in mammalian cells. DNA Repair 5: 1065-1074.
26. Vilenchik, M.M. & A.G. Knudson. 2003. Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc. Natl. Acad. Sci. USA 100: 12871-12876.
27. Neale, M.J. & S. Keeney. 2006. Clarifying the mechanics of DNA strand exchange in meiotic recombination. Nature 442: 153-158.
28. Kim, Y.G., J. Cha & S. Chandrasegaran. 1996. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. USA 93: 1156-1160.
29. Smith, J. et al. 2000. Requirements for double-strand cleavage by chimeric restriction enzymes with zinc finger DNA-recognition domains. Nucleic Acids Res. 28: 3361-3369.
30. Wolfe, S.A., L. Nekludova & C.O. Pabo. 2000. DNA recognition by Cys2His2 zinc finger proteins. Annu. Rev. Biophys. Biomol. Struct. 29: 183-212.
31. Jamieson, A.C., J.C. Miller & C.O. Pabo. 2003. Drug discovery with engineered zinc-finger proteins. Nat. Rev. Drug. Discov. 2: 361-368.
32. Pabo, C.O., E. Peisach & R.A. Grant. 2001. Design and selection of novel Cys2His2 zinc finger proteins. Annu. Rev. Biochem. 70: 313-340.
33. Porteus, M.H. 2006. Mammalian gene targeting with designed zinc finger nucleases. Mol. Ther. 13: 438-446.
34. Urnov, F.D. et al. 2005. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435: 646-651.
35. Notarangelo, L.D. et al. 2000. Combined immunodeficiencies due to defects in signal transduction: defects of the gammac-JAK3 signaling pathway as a model. Immunobiology. 202: 106-119.
36. Moehle, E.A. et al. 2007. Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. Proc. Natl. Acad. Sci. USA 104: 3055-3060.
37. Lombardo, A. et al. 2007. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 25: 1298-1306.
38. Banasik, M.B. & P.B. McCray, Jr. 2010. Integrase-defective lentiviral vectors: progress and applications. Gene Ther. 17: 150-157.
39. DeKelver, R.C. et al. 2010. Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res. 20: 1133-1142.
40. Pruett-Miller, S.M. et al. 2009. Attenuation of zinc finger nuclease toxicity by small-molecule regulation of protein levels. PLoS Genet. 5: e1000376.
41. Pruett-Miller, S.M. et al. 2008. Comparison of zinc finger nucleases for use in gene targeting in mammalian cells. Mol. Ther. 16: 707-717.
42. Gabriel, R. et al. 2011. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat. Biotechnol. 29: 816-823.
43. Pattanayak, V. et al. 2011. Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat. Methods 8: 765-770.
44. Doyon, Y. et al. 2011. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat. Methods 8: 74-79.
45. Miller, J.C. et al. 2007. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol. 25: 778-785.
46. Szczepek, M. et al. 2007. Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat. Biotechnol. 25: 786-793.
47. Miller, J.C. et al. 2011. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29: 143-148.
48. Cermak, T. et al. 2011. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 39: e82.
49. Christian, M. et al. 2010. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186: 757-761.
50. Moscou, M.J. & A.J. Bogdanove. 2009. A simple cipher governs DNA recognition by TAL effectors. Science 326: 1501.
51. Mussolino, C. et al. 2011. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 39: 9283-9293.
52. Pessach, I.M. & L.D. Notarangelo. 2011. Gene therapy for primary immunodeficiencies: looking ahead, toward gene correction. J. Allergy Clin. Immunol. 127: 1344-1350.
53. Pessach, I.M. et al. 2011. Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies. J. Allergy Clin. Immunol. 127: 1400-1407 e1404.
54. Zou, J. et al. 2009. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell. Stem. Cell. 5: 97-110.
55. Hockemeyer, D. et al. 2009. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 27: 851-857.
56. Hockemeyer, D. et al. 2011. Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 29: 731-734.